Skip to main content

ProQR Therapeutics N.V. (PRQR) Stock Forecast

Data as of May 10, 2026

Healthcare · Current price $1.59 (+0.95%)

Consensus Target
$3.63
Upside
+127.6%
Analysts
1
Rating
Buy(2.00)

Price Target Range

Low $2.00Consensus $3.63High $5.00
▲ Current $1.59

Consensus Price Target Over Time

Analyst Rating Distribution

Last 3 Months

Consensus
Buy
Strong Buy0
Buy1
Hold0
Sell0
Strong Sell0

6-Month Trend

Latest Analyst Forecasts

Price targets issued by Wall Street analysts. Upside calculated against today's price.

No analyst price targets available.

PRQR vs Sector & Market

MetricPRQRHealthcare AvgLarge Cap Avg
Analyst Rating2.002.242.41
Analyst Count1819
Target Upside+127.6%+1710.8%+16.4%
P/E Ratio-3.093.3027.60

Revenue Estimates

PeriodLowAvgHigh#
2026-06-30$4M$4M$4M3
2026-09-30$4M$4M$5M1
2026-12-31$4M$4M$4M2
2027-12-31$12M$18M$24M3
2028-12-31$67M$70M$73M3
2029-12-31$93M$120M$145M2
2030-12-31$350M$451M$543M1

EPS Estimates

PeriodLowAvgHigh#
2026-06-30$-0.14$-0.13$-0.125
2026-09-30$-0.15$-0.13$-0.111
2026-12-31$-0.16$-0.14$-0.121
2027-12-31$-0.86$-0.61$-0.405
2028-12-31$-0.68$-0.32$0.084
2029-12-31$0.06$0.08$0.112
2030-12-31$1.71$2.42$3.062

Frequently Asked Questions

What is the analyst consensus for PRQR?

The consensus among 1 analysts covering ProQR Therapeutics N.V. (PRQR) is Buy with an average price target of $3.63.

What is the highest price target for PRQR?

The highest analyst price target for PRQR is $5.00.

What is the lowest price target for PRQR?

The lowest analyst price target for PRQR is $2.00.

How many analysts cover PRQR?

1 analysts have issued ratings for ProQR Therapeutics N.V. in the past 12 months.

Is PRQR a buy or sell right now?

Based on 1 analyst ratings, PRQR has a consensus rating of Buy (2.00/5) with a +127.6% upside to the consensus target of $3.63.

What are the earnings estimates for PRQR?

Analysts estimate PRQR will report EPS of $-0.13 for the period ending 2026-06-30, with revenue estimated at $4M.

Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.